Ion Beam Applications SA (OTCMKTS:IOBCF) Short Interest Up 390.2% in July

Posted by Stanley Muller on Aug 14th, 2026

Ion Beam Applications SA (OTCMKTS:IOBCF – Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totaling 63,862 shares, a growth of 390.2% from the July 15th total of 13,027 shares. Based on an average trading volume of 319 shares, the days-to-cover ratio is presently 200.2 days.

Ion Beam Applications Price Performance

Shares of OTCMKTS:IOBCF remained flat at $19.00 on Friday. The company’s 50-day moving average is $18.94 and its 200 day moving average is $17.82. Ion Beam Applications has a 1-year low of $11.45 and a 1-year high of $20.10.

Hedge Funds Weigh In On Ion Beam Applications

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP purchased a new stake in shares of Ion Beam Applications during the 2nd quarter worth approximately $190,000. Simplicity Wealth LLC acquired a new stake in Ion Beam Applications during the 2nd quarter worth $205,000. Meeder Advisory Services Inc. acquired a new position in Ion Beam Applications in the second quarter valued at $236,000. EP Wealth Advisors LLC purchased a new position in shares of Ion Beam Applications during the second quarter worth about $271,000. Finally, Vise Technologies Inc. acquired a new stake in shares of Ion Beam Applications during the second quarter worth about $590,000. 14.86% of the stock is owned by institutional investors and hedge funds.

Ion Beam Applications Company Profile

(Get Free Report)

Ion Beam Applications (OTCMKTS: IOBCF) is a Belgium-based medical technology company specializing in the development and deployment of particle therapy solutions for cancer treatment. Founded in 1986 and headquartered in Louvain-la-Neuve, the company is best known for its Proteus® line of proton therapy systems, which are designed to deliver precise, high-energy particle beams that target tumors while sparing healthy tissue. IBA oversees the full project lifecycle, from system design and manufacturing to installation, commissioning, and ongoing service support.

In addition to its flagship proton therapy business, IBA operates a diversified portfolio of technologies for medical and industrial applications.